The question now for Biogen is whether that difference is sufficiently compelling to encourage patients to switch from Tecfidera, or to start with Vumerity rather than one of its rival therapies.

with the switch group showing a more modest result that was still better than the no-treatment arm. According to Eisai and Biogen, that level of change on the CDR-SB can be "the difference between ...

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:BIIB), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...

Biogen reported first-quarter profit that topped estimates as the company's cost-cutting efforts took hold and sales of its closely watched Alzheimer's drug, Leqembi, came in higher than expected ...

Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic ... hospitals have also experienced negative effects from the switch. Approximately half of the NHS hospitals treating MS patients ...